|
Online CME Activity
55 yo Man with Gastrointestinal and Cardiovascular Risks
|
NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
55 yo Man with Gastrointestinal and Cardiovascular Risks
Gastroenterology, GI Protection
2.00 AMA PRA Category 1 Credits™, 2.00 AANP
Learning Objective
Participants should be able to describe at least 2 risks for GI complications associated with use of antiplatelet agents alone and in combination with aspirin and other NSAIDs, and implement prevention and treatment strategies to minimize life-threatening GI complications from NSAIDs and antiplatelet agents.
Accreditation
This educational program is conceived and credited in accordance with ACCME’s Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute’s Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 2.00 |
AMA PRA Category 1 Credits™ |
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
Pri-Med Institute designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| 2.00 |
AANP |
Pri-Med Institute is approved as a provider of nurse practitioner continuing education programs by the American Academy of Nurse Practitioners. AANP Provider number 040308. |
This program has been approved for 2 contact hours of continuing education, which includes 1.0 hours of pharmacology. |
Faculty and Editorial Board
Written By:
James M. Scheiman, MD, Director, Endoscopic Ultrasound Program, Medical Procedures Unit, University of Michigan Hospital, Ann Arbor, MI;
Reviewed By:
University of Wisconsin School of Medicine and Public Health
Edited By:
Sally Farrand, Clinical Editor, Pri-Med Institute, Boston, MA;
Financial Disclosure Statement(s)
Dr Scheiman has received grant or research support from AstraZeneca; he has served as a consultant to AstraZeneca, Merck, McNeil, Novartis, TAP, Pfizer, The GI Company, Pozen, Bayer, and GSK; he has served on the Speakers' Bureau for AstraZeneca, TAP, and Santarus.
Ms Farrand has no financial relationships to disclose.
The content collaborators at INNOVIA Education Institute have no financial relationships to disclose.
Education Partner:
INNOVIA Education Institute, LLC
Pri-Med Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
|
|
